What is Korro Bio Debt-to-Equity?
Korro Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.99 Mil. Korro Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $31.22 Mil. Korro Bio's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $169.91 Mil.
Korro Bio's debt to equity for the quarter that ended in Dec. 2023 was 0.20.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Korro Bio's Debt-to-Equity or its related term are showing as below:
KRRO'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.03 Med: 0.08 Max: 0.2
Current: 0.2
During the past 3 years, the highest Debt-to-Equity Ratio of Korro Bio was 0.20. The lowest was -0.03. And the median was 0.08.
Korro Bio Debt-to-Equity Historical Data
The historical data trend for Korro Bio's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Korro Bio Debt-to-Equity Chart
|
Korro Bio Annual Data
|
|
Trend |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
- |
-0.03 |
0.20 |
|
Korro Bio Semi-Annual Data
|
|
Dec21 |
Jun22 |
Dec22 |
Jun23 |
Dec23 |
| Debt-to-Equity |
- |
N/A |
-0.03 |
-0.21 |
0.20 |
Competitive Comparison of Korro Bio's Debt-to-Equity
For the Biotechnology subindustry, Korro Bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Korro Bio's Debt-to-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Korro Bio's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Korro Bio's Debt-to-Equity falls into.
Korro Bio Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Korro Bio's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Korro Bio's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Korro Bio (Korro Bio) Business Description
Traded in Other Exchanges
N/A
Address
One Kendall Square, Suite 6-401, Building 600-700, Cambridge, MA, USA, 02139
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
Executives
| David L. Lucchino |
director, officer: President and CEO |
C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801 |
| Rick Yang |
10 percent owner |
2855 SAND HILL ROAD, MENLO PARK CA 94025 |
| Edward T Mathers |
10 percent owner |
C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
| Nessan Bermingham |
director |
890 WINTER STREET, WALTHAM MA 02451 |
| Atlas Venture Associates Xi, Llc |
10 percent owner |
400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
| Atlas Venture Associates Xi, L.p. |
10 percent owner |
400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
| New Enterprise Associates 17, L.p. |
10 percent owner |
1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
| Nea Partners 17, L.p. |
10 percent owner |
1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
| Nea 17 Gp, Llc |
10 percent owner |
1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
| Atlas Venture Fund Xi, L.p. |
10 percent owner |
400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
| Atlas Venture Opportunity Fund Ii, L.p. |
10 percent owner |
300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
| Atlas Venture Associates Opportunity Ii, Llc |
10 percent owner |
300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
| Atlas Venture Associates Opportunity Ii, Lp |
10 percent owner |
300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139 |
| Steve Colletti |
officer: Chief Scientific Officer |
C/O KORRO BIO, INC., ONE KENDALL SQUARE, BUILDING 600-700, CAMBRIDGE MA 02139 |
| Shelby J. Walker |
officer: See Remarks |
C/O KORRO BIO, INC., ONE KENDALL SQUARE, BUILDING 600-700, CAMBRIDGE MA 02139 |
Korro Bio (Korro Bio) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KRRO has been successfully added to your